ALK's house dust mite (HDM) sublingual allergy immunotherapy tablet has been approved in 12 European countries, to include availability for adolescent patients. Read More »
The U.S. FDA has issued a letter in response to the New Drug Application for baricitinib, rejecting the application. Read More »
Allergan PLC and Ironwood Pharmaceuticals Inc. merged forces with the American Gastroenterological Association to raise awareness about bowel health during Irritable Bowel Syndrome Awareness Month. Read More »
The U.S. Food and Drug Administration has approved two applications for treatments of hepatitis C in children. Read More »
Endo International announced April 12 a $300 million aggregate principal amount of 5.875% senior secured notes which will be due in 2024 at the price of $1000 for each $1000 principal amount, as related to their prior announcement of private offering. Read More »
An analysis commissioned by Washington, D.C.’s Pharmaceutical Care Management Association (PCMA) recently confirmed that no correlation exists between prices and rebates contrary to claims that drug costs are proportional to consumer rebates and discounts. Read More »
Imprimis Pharmaceuticals Inc. this month gained the rights to Klarity, a new remedy for dry eye disease (DED). Read More »
Amgen recently unveiled new data from the Kyprolis and Xgeva clinical development programs at the 16th International Myeloma Workshop in New Delhi. Read More »
A majority of the biggest patient advocacy groups in the country received drug industry funding last year, with many receiving as much as $1 million or more, a study has found. Read More »
The Academy of Managed Care Pharmacy (AMCP) recently applauded Rep. Brett Guthrie's (R-KY) Pharmaceutical Information Exchange (PIE) Act of 2017 and its efforts toward its passage. Read More »
Ingrezza (valbenazine) has been approved by the Food and Drug Administration for the treatment of tardive dyskinesia in adults. Read More »
A recent Walgreens study points to a connection between pharmacy communication and patient adherence. Read More »
CVS Health's Advanced Care Scripts has earned accreditation in Specialty Pharmacy from URAC, the leader in health care accreditation, certification and overall measurement. Read More »
Amgen's results from its Phase 3 Tower study evaluating Blincyto’s efficacy have been published in the New England Journal of Medicine. Read More »
Merck & Co. Inc. recently released the results of its Phase 3 clinical study of letermovir, a drug used to prevent clinically significant cytomegalovirus infection in CMV-seropositive adult recipients of an allogeneic hematopoietic stem cell transplant, also known as bone marrow transplant. Read More »
Sandoz, a division of Novartis, has selected six finalists for the Sandoz HACk Healthcare Access Challenge. Read More »
Biogen has entered into a licensing agreement for BMS-986168 with Bristol-Myers Squibb to initiate Phase II studies for the antibody treatment for Alzheimer’s disease and progressive supranuclear palsy. Read More »
AbbVie shared the successful results of its Phase IIb clinical trial on elagolix on patients suffering from heavy menstrual bleeding due to fibroids last week. Read More »
Tocagen Inc. recently announced that its Toca 511 & Toca FC drug received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Read More »
Shire plc recently delivered data at the American Academy of Allergy, Asthma & Immunology annual meeting on its Cuvitru drug, which treats patients with primary immunodeficiency. Read More »
Alerts Sign-up
